Allergie et asthme réfractaire : nouvelles pistes étiologiques et thérapeutiques

Cockcroft, 1996, Asthma control versus asthma severity, J Allergy Clin Immunol, 198, 1016, 10.1016/S0091-6749(96)80185-0 Global initiative for Asthma (Gina). Workshop report, global strategy for asthma management and prevention. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; November 2006. Wenzel, 2000, Proceedings of the ATS Workshop on refractory asthma: current understanding, recommendations and unanswered questions, Am J Respir Crit Care Med, 162, 2341, 10.1164/ajrccm.162.6.ats9-00 Pekkanen, 1999, Defining asthma in epidemiological studies, Eur Respir J, 14, 951, 10.1034/j.1399-3003.1999.14d37.x Burney, 1994, Related Articles, Links. The European Community Respiratory Health Survey, Eur Respir J, 7, 954, 10.1183/09031936.94.07050954 Pattemore, 2004, Asthma prevalence in European, Maori, and Pacific children in New Zealand: ISAAC study, Pediatr Pulmonol, 37, 433, 10.1002/ppul.10449 Neukirch, 1995, Prevalence of asthma and asthma-like symptoms in three French cities, Respir Med, 89, 685, 10.1016/0954-6111(95)90136-1 Com-ruelle L, Crestin B, Dumesnil S. L’asthme en France selon les stades de sévérité. Paris : CREDES, 2000 rapport no 1290. Auerbach, 1993, Total population survey of the frequency ad severity of asthma in 17 year old boys in an urban area in Israel, Thorax, 48, 139, 10.1136/thx.48.2.139 Woolcock, 1986, Worlwide differences in asthma prevalence and mortality, Chest, 90, 40, 10.1378/chest.90.5_Supplement.40S Miller, 2006, TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma, Eur Respir J, 28, 1145, 10.1183/09031936.06.00145105 Borish, 2005, Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma, Ann Allergy Asthma Immunol, 95, 247, 10.1016/S1081-1206(10)61221-5 The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003; 22: 470-7. Zureik, 2002, European Community Respiratory Health Survey. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey, BMJ, 325, 11, 10.1136/bmj.325.7361.411 Neukirch, 1999, Is sensitization to Alternaria Alternata a risk factor for severe asthma? A population based study, J Allergy Clin Immunol, 103, 709, 10.1016/S0091-6749(99)70247-2 Sandford, 2000, Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity, J Allergy Clin Immunol, 106, 135, 10.1067/mai.2000.107926 Pulleyn, 2001, TGF beta 1 allele association with asthma severity, Hum Genet, 109, 623, 10.1007/s00439-001-0617-y Jongepier, 2004, Polymorphisms of the ADAM 33 Gene are associated with accelerated lung function decline in asthma, Clin Exp Allergy, 34, 757, 10.1111/j.1365-2222.2004.1938.x Miranda, 2004, Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation, J Allergy Clin Immunol, 113, 101, 10.1016/j.jaci.2003.10.041 Ten Brinke, 2004, “Refractory”eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids, Am J Respir Crit Care Med, 170, 601, 10.1164/rccm.200404-440OC Kepley, 2001, Immunohistochemical detection of human basophils in postmortem cases of fatal asthma, Am J Respi Crit Care Med, 164, 1053, 10.1164/ajrccm.164.6.2102025 Carroll, 2002, Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma, Thorax, 57, 677, 10.1136/thorax.57.8.677 Pepe, 2005, Differences in airway remodeling between subjects with severe and moderate asthma, J Allergy Clin Immunol, 116, 544, 10.1016/j.jaci.2005.06.011 Carroll, 1996, Airway structure and inflammatory cells in fatal attacks of asthma, Eur Respi J, 9, 709, 10.1183/09031936.96.09040709 Berger, 2005, Mast cell myositis: a new feature of allergic asthma?, Allergy, 60, 1238, 10.1111/j.1398-9995.2005.00898.x Girodet, 2005, Immunoglobuline E et maladies respiratoires, Rev Mal Respir, 22, 967, 10.1016/S0761-8425(05)85728-6 Begueret, 2007, Inflammation of bronchial smooth muscle in allergic asthma, Thorax, 62, 8, 10.1136/thx.2006.062141 Ayres, 1998, Brittle asthma, Thorax, 53, 315, 10.1136/thx.53.4.315 ten Brinke, 2005, Risk factors of frequent exacerbations in difficult-to-treat asthma, Eur Respir J, 26, 812, 10.1183/09031936.05.00037905 O’Hollaren, 1991, Exposureto an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma, N Engl J Med, 324, 359, 10.1056/NEJM199102073240602 O’Driscoll, 2005, Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions, BMC Pulm Med, 5, 4, 10.1186/1471-2466-5-4 Denning, 2006, The link between fungi and severe asthma: a summary of evidence, Eur Respir J, 27, 615, 10.1183/09031936.06.00074705 Pulimood, 2007, Epidemic asthma and the role of the fungal mold Alternaria alternata, J Allergy Clin Immunol, 120, 610, 10.1016/j.jaci.2007.04.045 Dales, 2004, Influence of outdoor aeroallergens on hospitalization for asthma in Canada, J Allergy Clin Immunol, 113, 303, 10.1016/j.jaci.2003.11.016 Newson, 1997, Effect of thunderstorms and airborne grass pollen on the incidence of acute asthma in England, 1990–94, Thorax, 52, 680, 10.1136/thx.52.8.680 Girgis, 2000, Thunderstorm-associated asthma in an inland town in south-eastern Australia. Who is at risk?, Eur Respir J, 16, 3, 10.1034/j.1399-3003.2000.16a02.x Siroux, 2007, Environmental Factors for Asthma Severity and Allergy: results from the EGEA study, Rev Mal Respir, 24, 599, 10.1016/S0761-8425(07)91127-4 Blanc, 2003, The prevalence and predictors of respiratory-related work limitation and occupational disability in an international study, Chest, 124, 1153, 10.1378/chest.124.3.1153 Le Moual, 2005, Asthma severity and exposure to accupational asthmogens, Am J Respi Crit Care Med, 172, 440, 10.1164/rccm.200501-111OC Szczeklik, 2001, Aspirin-induced rhinitis and asthma, Curr Opin Allergy Clin Immunol, 1, 27, 10.1097/01.all.0000010981.95396.58 Nelson, 2003, Prospects for antihistamines in the treatment of asthma, J Allergy Clin Immunol, 112, S96, 10.1016/S0091-6749(03)01883-9 Mellerup, 2000, Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment, Clin Exp Allergy, 30, 1423, 10.1046/j.1365-2222.2000.00910.x Holgate, 2005, The anti inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation, J Allergy Clin Immunol, 115, 459, 10.1016/j.jaci.2004.11.053 Humbert, 2005, Traitement par anticorps anti-IgE de l’asthme allergique difficile à contrôler, Rev Mal Respir, 22, 983, 10.1016/S0761-8425(05)85729-8 Humbert, 2005, Benefits of omalizumab as add-on therapy in patients with asthma who are inadequatelly controlled despite best available therapy (Gina 2002 step 4 treatment): INNOVATE, Allergy, 60, 309, 10.1111/j.1398-9995.2004.00772.x